DNA/RNA

Description
Spans 89 kb; 21 exons; size of intron 1: 37,4 kb.
Transcription
5,23 kb mRNA; alternative splicing of exon 9 gives rise to two isoforms, KitA and Kit, that differ by the presence or absence of four aminoacids.
Protein
Description 976 aa; 145 kDa; type III receptor tyrosine kinase; contains an extracellular domains with 5 Ig-like loops, a highly hydrophobic transmenbrane domain (23 aa), and an intracellular domain with tyrosine kinase activity split by a kinase insert (KI) in an ATP-binding region and in the phosphotransferase domain.
Expression
Hematopoietic stem cells, mast cells, melanocytes, germ-cell lineages and ICCs (Interstitial cells of Cajal).
Localisation
Plasma membrane.
Function
SCF/MGF receptor with tyrosine kinase activity; binding of ligand (SCF) induces receptor dimerization, autophosphorylation and signal transduction via molecules containing SH2-domains.
Germinal
In piebaldism, and in familial gastrointestinal stromal tumours (see below).
Somatic
In aggressive mastocytosis, mast cell leukemia, ANLL with/without mast cell involvement, myeloproliferative disorders, colon carcinoma and gastrointestinal stromal tumours and germ cell tumors (GCCs). 
Implicated in
Piebaldism
Systemic mast cell disease (SMCD)
Disease Mast cell hyperplasia in the bone marrow, liver, spleen, lymph nodes, gastrointestinal tract and skin; gain of function mutations are detected in most patients. Prognosis Depending on the four clinical entities recognized: indolent form, form associated with hematologic disorder, aggressive SMCD and mast cell leukemia; leukemic transformation with mast cell involvement is characterized by rapid progression of disease with a survival time less than 1 year. Oncogenesis Clinical features of malignant hematopoietic cell growth are influenced by the time, the location of c-kit mutative events, and the number of associated lesions. 
Core binding factor leukemias (ANLL-
M2
To be noted
Note Loss of expression of c-KIT appears to be associated with progression of some tumors (melanoma) and autocrine/paracrine stimulation of the c-kit/SCF system may participate in human solid tumors such as lung, breast, testicular and gynecological malignancies.
